SAN DIEGO, Aug. 9 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. and Trine Pharmaceuticals, Inc. announced today that they have signed a license agreement providing Mpex exclusive rights to Trine's intellectual property in the field of bacterial efflux pump inhibitors (EPIs). Trine (successor company to Microcide Pharmaceuticals), in partnership with Daiichi Pharmaceuticals Co., Ltd., validated the opportunity for EPIs to significantly improve antibiotic therapy against resistant bacterial pathogens.
"By acquiring Trine's rights to important efflux pump inhibitor patents and proprietary data, we have considerably strengthened our intellectual property portfolio and our freedom to operate in the field of combination anti-bacterial agents," said Bill Gerhart, President and CEO, Mpex Pharmaceuticals. "The rights acquired from Trine cover the discovery, development and use of EPIs to improve antibiotic activity and will help position Mpex as a clear leader in this important therapeutic area."
"We were impressed by the significant progress and commitment at Mpex towards developing EPI/antibiotic combination agents," said Tim Noyes, Chief Operating Officer, Trine Pharmaceuticals. "The demonstrated capability of Mpex to move beyond discovery activities into a clinical development program makes Mpex an ideal partner for realizing value from our intellectual property rights in the EPI field."
About Mpex Pharmaceuticals:
Mpex Pharmaceuticals, Inc. is focused on the discovery and development of new anti-bacterial drugs that meet the growing clinical need created by multi-drug resistant bacterial pathogens. Efflux pumps are membrane proteins that enable bacteria to develop resistance against multiple classes of antibiotics, thus decreasing their utility and effectiveness. Mpex is focused on combining inhibitors of efflux pumps with antibiotics to significantly improve potency and prevent the emergence of resistance. The Company's first candidate is an aerosol entering Phase Ib/IIa clinical trials to treat bacterial respiratory infections in patients with cystic fibrosis and ventilator-associated pneumonia. Beyond this first product, the Company is discovering and developing EPIs that can be combined with multiple classes of antibiotics for other indications. For information: http://www.mpexpharma.com/
About Trine Pharmaceuticals:
Trine Pharmaceuticals is a privately held drug development company that develops and commercializes pharmaceutical products in the areas of renal and gastrointestinal diseases. Trine in-licenses development stage compounds with high potential as drug candidates, and establishes a development plan based on clearly defined decision points. Through a highly integrated project management approach to drug development, Trine can quickly and efficiently establish clinical proof of concept and advance a compound to successive clinical decision points, including filing a NDA.
Mpex Pharmaceuticals, Inc.
CONTACT: Bill Gerhart of Mpex Pharmaceuticals, Inc., +1-619-594-4070,email@example.com; or Jennifer Larson, +1-415-409-2729,firstname.lastname@example.org, for Mpex Pharmaceuticals, Inc.